(Q37851499)

24 August 2017

1 reference

title

Lixisenatide for type 2 diabetes mellitus (English)

1 reference

24 August 2017

0 references

1 reference

ChEBI release 2020-05-28

3

Tina Vilsbøll

1 reference

24 August 2017

Mikkel Christensen

1

0 references

Jens Juul Holst

object named as

Jens J Holst

series ordinal

4

0 references

Filip K Knop

series ordinal

2

object named as

Filip K Knop

1 reference

PubMed ID

21391833

24 August 2017

language of work or name

English

0 references

publication date

11 March 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

1 reference

24 August 2017

20

1 reference

24 August 2017

4

1 reference

24 August 2017

549-557

1 reference

Global estimates of the prevalence of diabetes for 2010 and 2030

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Islet cell function: alpha and beta cells--partners towards normoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Therapy: What evidence should guide the use of thiazolidinediones?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Diabetes and protein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Signal transduction of the GLP-1-receptor cloned from a human insulinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.562191

10.1517/13543784.2011.562191

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21391833